IBDEI0DG ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6172,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6172,1,3,0)
 ;;=3^Thyroiditis,Subacute
 ;;^UTILITY(U,$J,358.3,6172,1,4,0)
 ;;=4^E06.1
 ;;^UTILITY(U,$J,358.3,6172,2)
 ;;=^119376
 ;;^UTILITY(U,$J,358.3,6173,0)
 ;;=C73.^^30^388^37
 ;;^UTILITY(U,$J,358.3,6173,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6173,1,3,0)
 ;;=3^Malig Neop of Thyroid Gland
 ;;^UTILITY(U,$J,358.3,6173,1,4,0)
 ;;=4^C73.
 ;;^UTILITY(U,$J,358.3,6173,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,6174,0)
 ;;=E10.21^^30^388^8
 ;;^UTILITY(U,$J,358.3,6174,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6174,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,6174,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,6174,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,6175,0)
 ;;=E10.9^^30^388^12
 ;;^UTILITY(U,$J,358.3,6175,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6175,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,6175,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,6175,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,6176,0)
 ;;=E11.21^^30^388^17
 ;;^UTILITY(U,$J,358.3,6176,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6176,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,6176,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,6176,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,6177,0)
 ;;=E11.39^^30^388^18
 ;;^UTILITY(U,$J,358.3,6177,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6177,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complication NEC
 ;;^UTILITY(U,$J,358.3,6177,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,6177,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,6178,0)
 ;;=E11.43^^30^388^15
 ;;^UTILITY(U,$J,358.3,6178,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6178,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,6178,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,6178,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,6179,0)
 ;;=E11.59^^30^388^13
 ;;^UTILITY(U,$J,358.3,6179,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6179,1,3,0)
 ;;=3^DM Type 2 w/ Circulatory Complications NEC
 ;;^UTILITY(U,$J,358.3,6179,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,6179,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,6180,0)
 ;;=E11.618^^30^388^14
 ;;^UTILITY(U,$J,358.3,6180,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6180,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Arthropathy NEC
 ;;^UTILITY(U,$J,358.3,6180,1,4,0)
 ;;=4^E11.618
 ;;^UTILITY(U,$J,358.3,6180,2)
 ;;=^5002654
 ;;^UTILITY(U,$J,358.3,6181,0)
 ;;=E11.621^^30^388^16
 ;;^UTILITY(U,$J,358.3,6181,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6181,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,6181,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,6181,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,6182,0)
 ;;=E11.622^^30^388^20
 ;;^UTILITY(U,$J,358.3,6182,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6182,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,6182,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,6182,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,6183,0)
 ;;=E11.65^^30^388^19
 ;;^UTILITY(U,$J,358.3,6183,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6183,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,6183,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,6183,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,6184,0)
 ;;=E11.9^^30^388^21
 ;;^UTILITY(U,$J,358.3,6184,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6184,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,6184,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,6184,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,6185,0)
 ;;=E13.9^^30^388^22
 ;;^UTILITY(U,$J,358.3,6185,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6185,1,3,0)
 ;;=3^Diabetes Mellitus (Secondary) w/o Complications NEC
